These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19270316)

  • 1. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease.
    Kastrup J; Johansen JS; Winkel P; Hansen JF; Hildebrandt P; Jensen GB; Jespersen CM; Kjøller E; Kolmos HJ; Lind I; Nielsen H; Gluud C;
    Eur Heart J; 2009 May; 30(9):1066-72. PubMed ID: 19270316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial.
    Harutyunyan M; Gøtze JP; Winkel P; Johansen JS; Hansen JF; Jensen GB; Hilden J; Kjøller E; Kolmos HJ; Gluud C; Kastrup J
    Immunobiology; 2013 Jul; 218(7):945-51. PubMed ID: 23294528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease.
    Wang Y; Ripa RS; Johansen JS; Gabrielsen A; Steinbruchel DA; Friis T; Bindslev L; Haack-Sørensen M; Jørgensen E; Kastrup J
    Scand Cardiovasc J; 2008 Oct; 42(5):295-302. PubMed ID: 18615353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of YKL-40 increases in patients with acute myocardial infarction.
    Nøjgaard C; Høst NB; Christensen IJ; Poulsen SH; Egstrup K; Price PA; Johansen JS
    Coron Artery Dis; 2008 Jun; 19(4):257-63. PubMed ID: 18480670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma YKL-40 predicts 10-year cardiovascular and all-cause mortality in individuals with type 2 diabetes.
    Lin CH; Li HY; Jiang YD; Chang TJ; Chuang LM
    Clin Endocrinol (Oxf); 2013 Aug; 79(2):185-91. PubMed ID: 22901243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease.
    Mathiasen AB; Harutyunyan MJ; Jørgensen E; Helqvist S; Ripa R; Gøtze JP; Johansen JS; Kastrup J
    Scand J Clin Lab Invest; 2011 Sep; 71(5):439-47. PubMed ID: 21827355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum YKL-40 levels in patients with coronary artery disease.
    Kucur M; Isman FK; Karadag B; Vural VA; Tavsanoglu S
    Coron Artery Dis; 2007 Aug; 18(5):391-6. PubMed ID: 17627189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease.
    Zheng JL; Lu L; Hu J; Zhang RY; Zhang Q; Chen QJ; Shen WF
    Atherosclerosis; 2010 Jun; 210(2):590-5. PubMed ID: 20056225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial.
    Harutyunyan MJ; Mathiasen AB; Winkel P; Gøtze JP; Hansen JF; Hildebrandt P; Jensen GB; Hilden J; Jespersen CM; Kjøller E; Kolmos HJ; Gluud C; Kastrup J;
    Scand J Clin Lab Invest; 2011 Feb; 71(1):52-62. PubMed ID: 21108561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
    Schmidt H; Johansen JS; Sjoegren P; Christensen IJ; Sorensen BS; Fode K; Larsen J; von der Maase H
    J Clin Oncol; 2006 Feb; 24(5):798-804. PubMed ID: 16391295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population.
    Rathcke CN; Raymond I; Kistorp C; Hildebrandt P; Faber J; Vestergaard H
    Int J Cardiol; 2010 Aug; 143(1):35-42. PubMed ID: 19223085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease.
    Schroder J; Jakobsen JC; Winkel P; Hilden J; Jensen GB; Sajadieh A; Larsson A; Ärnlöv J; Harutyunyan M; Johansen JS; Kjøller E; Gluud C; Kastrup J
    J Am Heart Assoc; 2020 Mar; 9(5):e014634. PubMed ID: 32114892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased YKL-40 levels in patients with isolated coronary artery ectasia: an observational study.
    Erdoğan T; Kocaman SA; Çetin M; Durakoğlugil ME; Kırbaş A; Canga A; Yılmaz A; Doğan S; Çiçek Y
    Anadolu Kardiyol Derg; 2013 Aug; 13(5):465-70. PubMed ID: 23728225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum YKL-40 for monitoring myocardial ischemia after revascularization in patients with stable coronary artery disease.
    Harutyunyan M; Johansen JS; Mygind ND; Reuter SB; Kastrup J
    Biomark Med; 2014; 8(8):977-87. PubMed ID: 25343670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.
    Bergmann OJ; Johansen JS; Klausen TW; Mylin AK; Kristensen JS; Kjeldsen E; Johnsen HE
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8644-52. PubMed ID: 16361549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YKL-40 levels increase with declining ankle-brachial index and are associated with long-term cardiovascular mortality in peripheral arterial disease patients.
    Höbaus C; Tscharre M; Herz CT; Pesau G; Wrba T; Koppensteiner R; Schernthaner GH
    Atherosclerosis; 2018 Jul; 274():152-156. PubMed ID: 29783062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide.
    Lyngbæk S; Winkel P; Gøtze JP; Kastrup J; Gluud C; Kolmos HJ; Kjøller E; Jensen GB; Hansen JF; Hildebrandt P; Hilden J;
    Eur J Prev Cardiol; 2014 Oct; 21(10):1275-84. PubMed ID: 23723326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial.
    Iversen KK; Teisner B; Winkel P; Gluud C; Kjøller E; Kolmos HJ; Hildebrandt PR; Hilden J; Kastrup J;
    Atherosclerosis; 2011 Jan; 214(1):203-8. PubMed ID: 21093861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
    Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
    Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality.
    Mygind ND; Iversen K; Køber L; Goetze JP; Nielsen H; Boesgaard S; Bay M; Johansen JS; Nielsen OW; Kirk V; Kastrup J
    J Intern Med; 2013 Feb; 273(2):205-16. PubMed ID: 23140269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.